Introduction
We have implemented a study to improve the design of therapeutic vectors for prostate cancer, a disease affecting over 300 000 men and causing 40 000 deaths per year. 1 Gene therapy protocols have been hampered by low expression and a lack of specificity, resulting in concerns of efficacy and safety. One approach for circumventing these problems in prostate cancer gene therapy is to develop a prostate-specific vector with greatly enhanced transcriptional activity, which retains a high degree of tissue specificity. The concept is that if the vector is able to exclusively restrict therapeutic gene(s) expression to the prostate, then the vector, when inadvertently delivered to non-targeted organs, will remain transcriptionally silent. This targeted approach should reduce potential side-effects of cytotoxic gene therapy.
Normal, hyperplastic and malignant prostate epithelia specifically express the kallikrein protease prostate-specific antigen (PSA). 2 Serum levels of PSA are used clinically as a marker for diagnosis and management of prostate cancer. 3, 4 The PSA gene regulatory regions are prime candidates to direct prostate-specific expression. [5] [6] [7] The PSA regulatory region ( Figure 1a ) includes a proximal promoter (600 bp upstream of the transcription initiation site) which contains a TATA box and two functionally important AREs (AREs, binding sites for the transcription factor AR [8] [9] [10] [11] [12] ). This promoter alone exhibits tissue-specific expression in vitro in cell-based assays, although it is insufficient to direct prostate specific expression in vivo. 13, 14 It has been established that a 6 kb region upstream of the PSA gene contains all of the genetic information to direct prostate-specific expression in transgenic mouse experiments. 13, 15 Three important studies narrowed down smaller upstream enhancer regions within the 6 kb that conferred prostate-specific PSA gene expression. [5] [6] [7] An 1.6-kb enhancer (−5322 to −3738) containing putative recognition sites for AR, AP-1, and c-fos 5 and a smaller 822-bp enhancer fragment 7 (−4757 to −3935) were able to achieve maximal activity comparable to the entire 6 kb PSA regulatory region. The importance of this region was highlighted by the identification of an androgen-inducible DNase hypersensitive site (DHS II) centered at −4.2 kb, mapped in chromatin from LNCaP prostate cancer cells. 6 Functional analyses of the DHS II region revealed a minimal 440-bp core enhancer (−4324 to −3884), which provided strong enhancer activity and contains a high affinity ARE (AREIII 6 ). Subsequent studies demonstrated that the core enhancer contains at least four non-consensus AREs with variable binding affinity for AR, 16 all of which contribute to the synergistic activation of PSA gene expression. 16 Studies utilizing combinations of native PSA regulatory regions to drive therapeutic genes [17] [18] [19] in cell culture have demonstrated approximately a 10-fold prostate tissue discriminatory activity and androgen inducibility. The expected therapeutic response of tumor cell ablation was observed in PSA-expressing prostate cancer cells. Validating these prostate-specific therapeutic responses in animal models and patients will require a vector capable of efficient in vivo gene transfer to deliver the PSA promoter-driven therapeutic transgenes. Recombinant
Gene Therapy adenovirus vectors (Ads) have the capacity to deliver genes in vivo and intra-prostatically, 20 and also have been utilized in several on-going human prostate cancer clinical trials. 21, 22 Two Ads with either the entire 5.8-kb (−5825 to +12) PSA regulatory region or 1.6-kb (−5322 to −3738) enhancer linked to the proximal PSA promoter (−541 to +12), were able to direct either prostate-specific expression of cytotoxic HSVtk 19 or viral E1A 22 to induce lytic viral replication. The efficacy, tissue specificity and safety of these therapeutic approaches were not fully evaluated in vivo. Our studies illustrated that the native PSA enhancer and promoter (−5322 to −2855 and −541 to +11 of PSA gene) inserted into Ad could direct tissue specific and 10-fold androgen-inducible expression in LNCaP cells, but its transcriptional activity is lower than the constitutive CMV promoter by 50-fold or more (data not shown).
A basic understanding of transcription regulatory mechanisms is necessary to devise logical approaches to improve the activity and specificity of the PSA enhancer and promoter. Although the precise mechanism of PSA enhancer function is unclear, recent results clearly demonstrated that the compact and functionally important enhancer core (−4366 to -3874) contains a cluster of four non-consensus AREs 16 of two distinct classes (I and II   23 ). The class I and II sites each have distinctive nucleotide variations within the ARE that confer differential binding patterns and functions to AR. 23 Although the isolated class I sites have higher AR binding affinity than class II sites, binding to class II sites facilitates adjacent class I sites function resulting in cooperative AR binding to the tandem AREs. 23 This cooperative binding contributes to AR-mediated synergistic transcriptional activation. 16, 23 These studies lend support to the current idea that an enhanceosome composed of multiple activators engage in specific, cooperative and often combinatorial interactions, which lead to the assembly of a stable nucleoprotein structure that governs the specificity of transcription. Thus, it is plausible that AR anchors such a structure on to the PSA enhancer. [24] [25] [26] [27] In an attempt to harness the synergy and cooperative nature of AR bound to the transcriptional enhancer element, we undertook a systematic combinatorial manipulation of native and artificial enhancer elements. In one approach, we fused an artificial regulatory element (ARE4, Figure 1b ) comprising four tandem copies of a high affinity class I ARE (derived from 15 bp AREI site of PSA promoter 10 ) to the native PSA enhancer and promoter construct (PSE). In a second strategy, we duplicated the core enhancer. These two approaches in conjunction with the removal of intervening sequences (−3744 to −2855) to position the enhancer elements closer to the proximal promoter have resulted in greatly augmented transcriptional activity and tissue specificity. The several improved chimeric constructs mediate significantly higher (Ͼ10-fold) activity versus the PSE. More importantly, the augmented activity of our PSA enhancer construct is validated in a therapeutically relevant Ad.
Results

Concept of the chimeric enhancer
The goal of our study was to create prostate-specific gene therapy constructs with high activity and exquisite tissue specificity. The PSA enhancer contains a natural androgen inducible subregion centered 4.2-kb upstream from the transcription startsite (Figure 1b) . We reasoned that by combining this region with an artificial enhancer, or by duplicating the region, we could create a chimera with increased activity while retaining prostate specificity. To create the artificial enhancer, we multimerized the ARE I site found in the proximal PSA promoter region ( Figure  1a ). We hypothesize that this ARE4 should function synergistically with the enhancer core when transposed directly adjacent to it.
The parental construct, PSE, consisted of the 2.4-kb enhancer fragment (−5322 to −2855) and the proximal promoter region from −541 to +12, upstream of a luciferase gene. PSE was chosen to serve as the baseline construct because the 2.4-kb enhancer fragment generates the maximal transcriptional and androgen responsive activity, comparable to the entire 6-kb regulatory region of the PSA gene. 6 The androgen inducible core region bearing four natural AREs is defined by two flanking restriction sites, BstEII and NcoI (−4326 to −3935). We constructed the following reporter gene variants: one lacking the core enhancer (PSA-ARE0); one containing ARE4 in place of the core (PSE-ARE1); one in which ARE4 was inserted immediately downstream of the enhancer core at −3935 (PSE+A); and finally, a construct bearing a duplicated core region, where an additional copy of the core was placed upstream at −4326 (PSE+C). We also postulated that removing the sequence between the enhancer and promoter would increase activity further. This set of constructs is termed the PSE-B series. Figure 1b is a schematic representation of all the constructs tested.
Activities of chimeric constructs
The constructs were tested initially in cell culture transfections by analyzing three criteria: transcriptional activity, androgen inducibility and cell specificity. Relative activities of the constructs were compared by transfections in LNCaP cells (an AR+, PSA+ prostate cancer cell line) in the presence of 1 nm synthetic androgen R1881. PSE exhibited low to modest absolute activity in LNCaP cells, approximately 4% CMV activity (data not shown). Figure 2a displays the activities of all constructs relative to PSE (= 1). The activity was enhancer dependent because removal of the core region abolished transcription to 10% of PSE. Addition of ARE4 in place of the core did not restore activity. However, the positioning of ARE4 adjacent to the core (PSE+A) led to a substantive 3.3-fold increase in activity over the baseline PSE. Duplication of the core in PSE+C also enhanced activity by 1.9-fold. In summary, the data bore out the premise, that ARE4 in combination with the core would synergize with the natural region to raise PSA enhancer activity. Figure 2b shows that removing the intervening DNA augments the activity of all the constructs from the parental to the chimeric constructs. Removal of sequences −3744 to −2875 from PSE raised the activity by 2.2-fold (PSE-B). Further combinatorial modifications drastically enhanced activity 7.3-, 18.7-and 9.4-fold higher than PSE in PSE-BA, PSE-BC and PSE-BAC, respectively. Recapitulating the stimulatory effects by removal of intervening sequences, PSE-BA and PSE-BC achieved an additional 2.2-and 9.8-fold augmentation over their extended counterparts PSE+A and PSE+C.
Androgen inducibility and tissue specificity in chimeric constructs
The chimeras exhibited greatly increased androgen inducibility. Figure 3a presents the androgen induction of all the constructs, calculated by comparing the luciferase activity of LNCaP cells transfected in the presence of 1 nm R1881 over those transfected in the absence of androgen, ie cells maintained in charcoal-stripped serumcontaining media. The higher activities of the chimeric constructs are illustrated by enhanced androgen responsiveness over the parental PSE. This point is best illustrated by PSE-BAC, PSE-BC and PSE-BA, the three most active constructs. They exhibited the highest androgen inducibility from 96-to 201-fold. The basal activities of all constructs in the absence of added androgen are not significantly higher than that of PSE. PSE-B exhibits the highest increase of basal activity, at 3.6-fold higher relative to PSE; and PSE-BA, PSE-BC, PSE-BAC are 1.03-, 1.9-and 1.2-fold higher, respectively. Variations of basal activities were observed in different experiments and could be attributed to difficulties in depleting all androgen from the media. Figure 3b shows the results from a separate transfection experiment, where to validate that PSE-BAC retained normal responsiveness it was compared with the parental PSE for androgen inducibility. As the androgen concentration in the culture was increased, the activation profile of the chimeric and parental constructs paralleled each other. The activities of the constructs were negligible at 0.1 nm, gradually increased from 0.1 to 1 nm, and peaked at 10 nm. PSE-BAC induced 232-fold at 1 nm R1881, compared with 16.7-fold for the parental, as shown on the vertical axis of the graph. These results argue that the augmented transcriptional activity of the chimeras is indeed due to Gene Therapy
Figure 3 Androgen inducibility. (a) The androgen inducibility of the chimeric constructs is greater than that of PSE. LNCaP cells, aliquoted into 24-well plates, were changed to androgen depleted media (RPMI + 10% charcoal stripped FBS) 24 h before transfection. After transfections, wells were replaced with the same androgen depleted media or with 1 nm R1881 added. Fold of androgen induction is calculated by the ratio of luciferase activity in androgen-containing over androgen-depleted media for each construct. (b) PSE and PSE-BAC were transfected into LNCaP cells and the indicated concentrations of R1881 were added. The vertical axis represents fold induction versus PSE measured in the absence of R1881.
increased androgen responsiveness as predicted by our original hypothesis.
All of the chimeras retain cell-type selectivity in culture. Our most active constructs were compared via sideby-side transfections into either MCF-7 cells, a breast cancer line, HeLa cells, a cervical carcinoma line, and LNCaP cells, all in the presence of 1 nm R1881. The luciferase activities were normalized to the CMV promoter in the respective cell lines. All constructs exhibited negligible activity in the presence of 1 nm R1881 in MCF-7 and HeLa cells (Figure 4a) , ranging from 0.3% to 0.9% of CMV. However, under the same androgen-containing growth conditions in LNCaP cells, the parental and chimeric constructs elicited two to three orders of magnitude higher activities, respectively. For example, the activity in LNCaP over MCF-7 and HeLa PSE was 394-and 462-fold higher, respectively. From multiple transfection experiments using two different reagents, the activity of PSE and PSE-BC was 4% and 75% of CMV, respectively, in the presence of 1 nm R1881. This tissue-specific activity is not due solely to the presence of AR in LNCaP since MCF-7 cells contain low levels of AR 9,28 but fail to activate the reporters.
To investigate the contribution of AR to the tissue specificity of PSA enhancer constructs, we utilized a HeLa cell line engineered to stably express epitopetagged AR (fAR-HeLa 16 ) at a two-fold higher level than LNCaP. Constructs transfected into fAR-HeLa cells were androgen responsive (Figure 4b ) but to a much lower extent than in the prostate cancer cell line LNCaP ( Figure  3a) . The observed induction of 3.2-to 12.1-fold in fARHeLa is at least 10 times lower than the activity observed in LNCaP cells, with PSE-BA exhibiting the highest androgen inducibility. In the presence of androgen, the activity of PSE-BC and PSE-BAC was 4% and 8% of CMV, respectively. These results suggest that fAR-HeLa cells are lacking prostate-specific factors that amplify the androgen responsiveness in LNCaP. Alternatively, Hela cells may possess transcriptional suppressors not present in LNCaP.
Recruitment of AR and co-activators correlates with enhanced activity
The augmented activity of the constructs in transfections correlates with their ability to recruit AR and critical coactivators in vitro ( Figure 5 ). An immobilized template approach was applied to study recruitment of AR and cofactors in vitro in LNCaP extracts. The relevant regulatory regions were biotinylated and immobilized in equal amounts on streptavidin magnetic beads. The immobilized templates were then incubated in LNCaP nuclear extracts. Unbound protein was removed by washing, and the bound proteins were analyzed by immunoblotting with antibodies against AR and SRC-1. Little or no AR was detected bound to PSE-ARE0 in any of several repetitions of this experiment. The immunoblots show, however, that PSE and PSEARE1 recruit low but similar levels of AR, as expected as they contain similar numbers of AREs. PSE+A, and PSE+C recruit substantial amounts of AR again as expected. The blot shows that PSE+C can recruit the AR co-activator SRC-1 although longer exposures showed that PSE+A recruits about half as much.
The chimeric enhancers retain activity in the context of adenoviral vectors
When selected constructs were inserted into Ads, they retained regulated transcriptional activity and cell type selectivity. We chose to compare the activity of our most efficacious construct PSE-BC with that of PSE-B because a previously described prostate-specific Ad, currently being evaluated in a clinical study, 22 comprises almost the precise enhancer and promoter sequences as PSE-B. The recombinant Ads were generated by in vivo homologous recombination. 29 A schematic representation of the Ad is shown in Figure 6a . Prostate and non-prostate cells were equivalently infected with an MOI 5 (five infectious units/cell) of AdPSE-Bluc or AdPSE-BCluc. The similarity in infection efficiency was evident by similar levels of intracellular viral DNA measured by Southern blotting ( Figure 6b ). In the presence of androgen in LNCaP cells AdPSE-BCluc activity, as reflected by luciferase units, was 11.9-fold higher than AdPSE-Bluc (Figure 6c ). The androgen inducibilities of AdPSE-Bluc and AdPSE-BCluc were 27-and 281-fold, respectively. Both constructs retained strict tissue-specific activity as expression in R-11 (a renal carcinoma line), 30 MCF-7 and HeLa cells were negligible despite our observation that these three lines are all readily infected by Ad. The adenoviral infectivity was estimated by infection of cells with an Ad-expressing green fluorescent protein (AdCMV-GFP 31 ) at MOI 5. Infected LNCaP, R-11, MCF-7 and HeLa cells were 75%, 80%, 90% and 75% GFP positive, respectively (data not shown). The activity of AdPSE-BC was 5.7% of AdCMVluc. The lowered activity of PSE-BC relative to CMV in Ad compared with plasmid construct is unclear (see Discussion). Overall, the augmented activity, androgen responsiveness and tissue-discriminatory capability of Gene Therapy our constructs in Ad correspond very well with transfection analyses in tissue culture cells.
Assessment of tissue discriminatory activity of AdPSE-
BCluc in an animal model LAPC-9 and -4 are novel human prostate cancer xenografts that accurately retain clinical characteristics of human disease, including (1) their requirement of androgen for growth; (2) synthesis of PSA; (3) AR expression; (4) progression to androgen independence upon androgen withdrawal; and (5) ability to develop metastatic disease. 32 SCID mice were grafted with LAPC-9 32,33 tumors in their flanks. Three and five LAPC-9 tumor-bearing mice were injected via the tail-vein with 1.8 × 10 9 infectious units of AdCMV-luc and AdPSE-BC-luc, respectively. Luciferase expression in different mouse tissues was measured 3 days after Ad injection. Consistent with previous studies, 34 AdCMV-luc injected animals dis- played high level expression, predominantly in the liver with a precipitous decrease of more than 500-fold expression within all other organs, ie lung, kidney, prostate and LAPC-9 tumors (Figure 7a ). In contrast, the tissue expression profile of AdPSE-BCluc (Figure 7b) showed very low activity in the liver compared with AdCMV-luc. Despite a 1000-fold lower viral delivery (estimated by AdCMV-luc results) to distal tissues such as prostate or LAPC-9 tumors, luciferase expression was clearly evident (Figure 7b ). In conclusion, the tissue discriminatory activity of our AdPSE-BC-luc was demonstrated in an animal model system. This work should pave the way for the development of prostate-specific gene therapy vectors with improved activity and safety parameters for clinical applications.
Discussion
Specific transcriptional targeting strategies are beneficial in gene therapy applications, because restricting the expression of toxic therapeutic genes to malignant prostate cells provides additional safety measures over constitutive expression strategies. However, the transcriptional output from the native PSA enhancer and promoter, and from most highly regulated tissue-specific promoters, is much lower than from strong constitutive viral promoters such as CMV. Our goal was to manipulate promoter and enhancer activity to achieve both high and specific gene expression to achieve safe and effective gene therapy in vivo.
Over the past decade well-defined mechanisms of gene activation have emerged from studies in the transcription field. Cooperative binding of multiple sequence-specific transcription factors to the proximal promoter and distal enhancer of a gene, and subsequent recruitment of coactivator proteins, lead to the assembly of a large general transcription initiation complex over the start site of a gene. 25, 35 Enhancer-mediated transcription activation is likely achieved by further cooperative interactions between the enhancer and the promoter complex, via looping out the intervening DNA. The strong cooperative regulation of initiation complex assembly is believed to be responsible for tissue-specific gene expression. 36 The precise mechanism of how the PSA regulatory elements orchestrate an accurate and prostate-specific transcription program is incompletely understood, but one essential component of enhancer activation function is mediated through cooperative AR-AR interactions. 16, 23 Studies have also pointed to the involvement of both prostatespecific and ubiquitous transcription factors in cellspecific regulation. 5, 6, 37 We manipulated the known PSA regulatory components, namely the proximal 600-bp promoter, the enhancer core centered at −4.2 kb, and high affinity AREs, to achieve augmented prostate specific expression. The three strategies we utilized (1) insertion of ARE4; (2) duplication of the enhancer core element; and (3) removal of intervening sequences between the enhancer and promoter, all increased transcription activity and androgen inducibility. The manipulations resulted in three highly active constructs, PSE-BA, PSE-BC and PSE-BAC, exhibiting up to 18.9-fold higher activity, and up to 201-fold higher androgen inducibility, relative to our baseline PSE construct. Moreover, the constructs retained a high degree of tissue discriminatory capability such that their expression is much higher in LNCaP androgen-responsive prostate cells than non-prostate, AR expressing cells.
Juxtaposing the synthetic ARE4 immediately 3Ј to the enhancer core in our chimeric constructs (PSE+A, PSE-BA and PSE-BAC) achieved the desired effect of enhanced activity over the baseline PSE construct. The ARE4 synergizes with the enhancer core element to activate transcription. The increase was synergistic because the core or ARE4 on its own elicited only modest or no activity respectively (ie activity of PSE to PSE-ARE0 is 10 and PSE-ARE1 to PSE-ARE0 is 1, see Figure 2a) . However, the combination of core and ARE4 (PSE+A to PSE-ARE0) resulted in 33-fold enhancement, which is greater than an additive effect. One step in the mechanism of activation involves increased binding of AR to the chimeric enhancer element (see Figure 5 ), which in turn likely induces interactions of a co-activator, such as SRC-1.
Although the PSE-BAC construct contains the ARE4 element in addition to a duplicated enhancer core, its activity is slightly lower than PSE-BC. It is unclear whether the deletion of an additional 190 bp (−3935 to −3744) in PSE-BC (ie the sequence replaced by ARE4 in PSE-BAC; see Materials and methods for details), contrib-utes to the lower than expected level of activity. A binding site for a novel prostate-specific Ets-family transcription factor, PDEF, is located at −3848 in the midst of the deleted sequences. 37 Although transient expression of PDEF augmented PSA promoter activity in prostate cells and non-AR expressing cells, 37 the precise contribution of PDEF to PSA promoter function requires further clarification.
The PSA enhancer core region (−4326 to −3955) mediates transcriptional activation in a prostate-specific manner, working in concert with the proximal promoter. This point is illustrated by results in Figures 2b and 4a , where an additional copy of the enhancer core greatly increased transcriptional output in androgen-responsive prostate cells, but exhibited no detectable effect in nonprostate cells. Although multiple AREs within the enhancer core contribute greatly to its activity, 16 there are almost certainly undefined components within this element that govern prostate-specific transcriptional activity. 5, 6, 37 This point is emphasized by the observation that replacing the deleted core (PSE-ARE0) with the ARE4 element (PSE-ARE1) did not rescue its activity in the cell types presented here. Therefore, we conclude that the chimeric constructs achieve their effect by combining the transcription stimulatory activity of ARE4 with the prostate specificity of the core element, a point substantiated by our various constructs.
A similar theme has emerged in two recent studies, validating the concept that multimerization of key promoter or enhancer elements improves prostate-specific transcriptional activity. 38, 39 Constructs with three copies of the androgen-responsive region (ARR, −244 to −96) of the rat probasin promoter that contained multiple class I and II AREs 23 exhibited about 20-fold higher activity than when a single ARR was linked to minimal promoter reporter construct. 38 Studies presented in Latham and colleagues' paper involved constructs that multimerized the larger 1.4-kb PSA enhancer fragment (−5322 to −3869) and linked it to the 600-bp PSA proximal promoter. The most active construct (GL3 E2 PSA) exhibited an approximately four-fold increased activity over a construct with a single enhancer fragment (GL3-E-PSA) in LNCaP cells. This approach is similar to our strategy for generating PSE-BC, except our duplicated sequences (−4326 to −3935) are more than 1 kb smaller. Accurate comparison of their results with our study is difficult because the methodology and the baseline constructs are different. However, a relative comparison of activity indicates that duplication of the much smaller 390-bp enhancer core appeared to be more effective than duplicating the larger 1.4-kb fragment. As illustrated in Figure 2b , PSE-BC activity is 18.9-fold higher than PSE and 8.5-fold higher than PSE-B, which contains an enhancer (−5322 to −3744) region similar to the GL3-E-PSA (−5322 to −3869) construct. Interestingly, three copies of the 1.4-kb enhancer resulted in diminution of activity. 39 We observed the same phenomenon as either three or four copies of the enhancer core diminished activity below PSE (data not shown). Mechanistically, it is interesting to speculate that too many binding sites for transcription factors might disperse limiting factors or co-activators to locations that reduce cooperative interactions and functionality.
Because Ads are capable of efficient gene transfer in vivo, then demonstrating that the improved activity and specificity of our modified PSA enhancer plasmid conGene Therapy structs are retained in an Ad is an important step. It is unclear why the PSA promoter-derived constructs in Ad exhibit diminished activity relative to CMV-driven constructs. Several plausible explanations include: (1) template number differences per cell in transfection versus infection conditions; (2) different DNA-nucleosome structures of Ad versus transfected plasmid DNA; (3) adenoviral sequences might suppress transcription. The combination of improved vector strategies, such as gutless Ad devoid of all coding sequences, 40 cell-surface targeted Ad 41 or non-viral lipid complexes, 42 with our chimeric PSA enhancers could produce prostate cancer gene delivery vectors with further augmented activity and specificity.
Proper transcriptional regulation of our Ad in relevant human prostate cancer models such as LAPC-4 and LAPC-9 is important as these models can also be established in androgen independent (AI) conditions that mimick advanced stages of disease progression. Our Ad is not active in AR negative cells, ie DU145 and PC-3 prostate cancer cells. On the other hand, as illustrated in Figure 4a and b, the presence of AR alone is not sufficient for maximal transcriptional activity. Recent clinical and laboratory investigations point to AR-mediated signaling in advanced AI disease even under androgen-depleted conditions. [43] [44] [45] [46] We will be evaluating the activity of our vectors thoroughly in AI models. The precise magnitude of therapeutic gene product needed to mediate effective tumor eradication could be very different, depending upon the therapeutic strategy. For example, in strategies with amplification effects, such as immune stimulatory approaches or viral oncolysis, a high level of expression is probably not as crucial as compared with growth suppressive or cytotoxic schemes.
To implement a quantitative and non-invasive method capable of monitoring transgene expression in living animals repetitively would be a crucial step toward validating the efficacy of any gene therapy strategy. A positron emission tomography (PET) approach, based on herpes simplex virus 1 thymidine kinase (HSV1tk) trapping of positron-labeled substrates, has been demonstrated to be a sensitive and quantitative modality to image the location and magnitude of Ad-mediated HSV1tk gene expression in living animals. 47, 48 The advent of better human prostate cancer models, advanced gene expression imaging technology and improved prostatespecific vectorology could lead to an era where a safe and effective prostate cancer gene therapy protocol is a reality.
Materials and methods
Cell culture
The LNCaP, MCF-7 and R-11 cells were grown in RPMI 1640 (Gibco-BRL, Gaithersburg, MD, USA) with 10% FBS (Gemini Co, Woodlands, CA, USA) and 100 units/ml of penicillin and streptomycin. The R-11 renal carcinoma cell line was derived from a patient with kidney cancer. Androgen induction analyses were accomplished by replacement of FBS containing media to media containing 10% charcoal/dextran stripped FBS, 7 1 day and 4 h before transfection or infection. Changing the media twice was to ensure removal of trace amount of androgen in media. Methyltrienolone, R1881, (NEN Life Science Products, Boston, MA, USA) dissolved in ethanol was added to the 10% charcoal stripped FBS containing media at specified concentration after transfection or infection.
Plasmid constructs
The starting baseline construct pPSE were constructed in a modified pBS II SK+ (Stratagene, La Jolla, CA, USA) where the Asp718 site is converted to a NotI site. By design the insertion of a NotI flanked PSA enhancer/promoter expression cassette (spanning from upstream enhancer to the end of polyA element) removes all restriction sites between Asp718 to NotI of pBS. We then inserted multiple cloning sites encoded by oligonucleotides (HindIII, EcoRV, EcoRI, Asp718, SwaI and SalI) between the PSA enhancer/promoter and SV40 polyA to facilitate insertion of different transgenes. The PSA enhancer/promoter fragment, 5Ј NotI to 3Ј HindIII derived from plasmid PSAR2.4k-PCPSA-P-Lux, 7 contains PSA regulatory region from −5322 (XbaI) to −2855 joined to proximal promoter −541 (BglII) to +12 (HindIII). The SV40 polyA, 5ЈHindIII to 3ЈNotI, fragment is derived from pACCMVpLpASR. 49 The ARE4 157 bp synthetic element was generated by first ligating and multimerization of paired oligonucleotides containing the 15 bp AREI. The paired primers and PCR were used to incorporate the designed terminal restriction sites and the precise nucleotide sequence of ARE4 was confirmed. The ARE4 sequence is flanked by two NcoI sites and also contained a BstEII and a BamHI site immediately 3Ј of the 5Ј NcoI site (see Figure 1b) . Insertion of this ARE4 synthetic sequence into the unique NcoI site (−3935) of pPSE resulted in two orientations of PSE+A. Both orientations of PSE+A have comparable activities (data not shown). The orientation of PSE+A, where the BstEII site of ARE4 is more distal to −3935 NcoI (PSE+A/−) was retained and analyzed in all subsequent studies. The control PSE-ARE0 was generated by cutting PSE+A/− with BstEII and religation which removed the enhancer core region. The other orientation of PSE+A where the BstEII site is immediately 3Ј to −3935 (PSE+A/+) was utilize to generate the enhancer core fragment from −4326 to −3935 flanked by two BstEII sites and pPSE-ARE1. Insertion of this BstEII enhancer core fragment (and its multimers) into the unique BstEII at −4326 of pPSE resulted in PSE+C construct (and three or four copies of core). The control construct pPSE-ARE1 was generated by religation of BstEII restricted pPSE+A/+, resulted in ARE4 replacement of the enhancer core.
The PSE-B series of plasmids were generated by cutting with BamHI and BglII, followed by religation since the two enzymes have compatible ends. This manipulation of PSE, PSE+C resulted in the removal of enhancer sequence from −3743 (BamHI) to −2855, thus linking −3744 directly to −541 (BglII) of proximal promoter of PSE-B and PSE-BC. The same BamHI to BglII deletion in PSE+A resulted in extended sequence removal, −3935 to −2855 in PSE-BA, because of the presence of a BamHI site in the ARE4 sequence. PSE-BAC was generated by insertion of the BstEII flanked enhancer core fragment into PSE-BA. The HindIII to EcoRI luciferase gene derived from pSP-luc+ (Promega, Madison, WI, USA) was inserted into all the PSA enhancer/promoter constructs for activity assays.
Transfections and DNA analysis 5 × 10 4 HeLa, MCF-7 or R11 cells or 1 × 10 5 LNCaP cells were plated into 24-well plates 48 h before transfection. The activity of the different constructs, each bearing a downstream luciferase reporter gene, was assayed by transfection using the lipid reagent Lipofectamine Plus (GibcoBRL) or Tfx 50 (Promega) into cells. Assays in quadruplicate were performed according to the manufacturer's guidelines and the two reagents gave comparable results. One day after transfection, the cells were harvested and lyzed in 100 l of 1 × passive lysis buffer according to the manufacturer's instructions (Promega). 10 l of cell lysate from each transfection was measured by luminometry (luminometer: Monolight 2010, Analytical Luminescence Laboratory, San Diego, CA, USA). Relative luciferase activity was calculated in reference to PSE which was assigned a value of 1 (100 000 to 200 000 luciferase activity in presence of 0.1 nm R1881). We chose this designation so that the augmented activity of the chimeric constructs could be directly compared with PSE.
A modified Hirt DNA isolation procedure 50, 51 was used to obtain low molecular weight DNA from cells 24 h after adenovector infection. An aliquot of each infected cell culture was also analyzed for luciferase expression. Hirt DNA from 10 6 LNCaP cells infected at MOI 5 (virus:cell ratio = 5) was analyzed by Southern blot using nonradioactive digoxigenin-labeled luciferase DNA probe (Roche Molecular Biochemicals, Mannheim, Germany). Transferred DNA on nylon membrane (Hybond; Amersham Pharmacia, New Jersey, USA) was detected by colorimetric conversion of NBT and BCIP. All procedures were performed according to the manufacturers' protocols.
Recombinant adenoviruses
To generate recombinant adenovector, the NotI luciferase expression cassettes from PSE-Bluc and PSE-BCluc were cloned into the pACCMVpLpASR 49 replacing the NotI CMV expression cassette, resulting in the pAC-PSE-Bluc and pAC-PSE-BCluc, respectively. The pACCMV pLpASR 48 contains Ad5 DNA from nt 1 to 454, NotI CMV expression cassette and Ad5 DNA nt 3334 to 6231. Cotransfection by CaPO 4 method 29 of either pAC-PSE-Bluc or pAC-PSE-BCluc with pJM17 52 and subsequent in vivo homologous recombination between the two transfected plasmids in 293 monolayer cells resulted in the emergence of respective recombinant adenovectors, Ad-PSEBluc and Ad-PSE-BCluc. A single isolated viral plaque was expanded and screened by restriction digestion analysis of viral DNA prepared by Hirt isolation from infected cells. Confirmed viral clones were plaque-purified in three successive rounds. Viral stocks were prepared by large-scale infection of 293 suspension cultures. Virus was purified by CsCl 2 step gradient ultra-centrifugation, dialzyed to remove CsCl 2 , and resuspended in 10 mm Tris (pH 7.5), 10% glycerol and 10% FBS and stored at −80°C. Infectious viral titers were determined by plaque formation units (p.f.u.) on 293 monolayer cells. 29 
Immobilized template pulldown assay
The basic concept of this assay is to compare the binding of relevant transcription factors or co-activators from LNCaP nuclear extracts to each immobilized enhancer template construct. LNCaP nuclear extracts were prepared according to Huang et al. 16 Biotinylated DNA containing the key enhancer core region from each of the specified constructs was generated by PCR using a pair of primers corresponding to −4383 XXCAGACAGCAT-GAGGTTCATGTTCACA −4358 (5Ј primer, X = biotin) and −3894 GGGTGGAAGGCTCTGGCTGAACAGCGT −3920 (3Ј primer). Streptavidin solid support beads (30 l from Dynal) were washed twice in buffer containing 10 mm Tris-HCl, 1 mm EDTA and 2 m NaCl. Each biotinylated template DNA was allowed to bind to 30 l of washed strepavidin beads for 60 min at room temperature. The beads were washed in buffer and resuspended in 0.1 m buffer D. 53 The precise template concentration bound to beads was quantified by digestion of 5 l of beads with HindIII, the beads were run on a 1.5% agarose gel and the concentration estimated by comparison with standards. LNCaP nuclear extracts (NE) were pre-incubated with pGEM3 (Promega), at a ratio 50 l NE to 100 ng pGEM3 for each reaction, by rotating 10 min at 4°C to eliminate non-specific binding. This NE was desalted and pre-cleared by passing through Microbio spin 6 columns (Bio-Rad, Hercules, CA, USA) which had been equilibrated with 0.1 m buffer D. 100 fmol of each immobilized template was incubated with 50 l of pre-cleared and desalted NE by incubating 45 min at 4°C. After binding the beads were washed twice with 200 l of buffer containing 125 l buffer D, 53 15 l 0.1 m MgCl 2 , 10 l 1% NP-40, 2 l of 50 g/ml BSA and 48 l ddH 2 O. Proteins bound to the solid templates were eluted directly by boiling in 2 × loading dye and resolved on standard Western blot analysis. The anti-AR (Santa Cruz, Santa Cruz, CA, USA) and anti-SRC1 (Santa Cruz) antibodies were used to detect the respective proteins.
Animal experiments LAPC-9 xenografts were passaged and grown subcutanously in male SCID mice as previously described. 33, 34 When tumors reached approximately 5-10 mm diameter, animals were injected via tail-vein with 1.8 × 10 9 p.f.u. of AdCMV-luc or AdPSE-BC-luc suspended in 100 l of PBS. Three days after Ad injection, animals were killed and organs were harvested and placed in 400-800 l of 1 × passive lysis buffer (Promega) with complete mini protease inhibitor cocktail (Roche). Homogenizations of the tissue were performed by a PowerGen 125 (Fisher Scientific) Protein concentrations of tissue homogenized lysates were measured by Coomassie Plus reagent (Pierce) according to the manufacturer's directions. 10-20 l of tissue lysate were measured in luminometer assays.
